Prostate cancer;Cancer de la prostate

Cancer/Radiotherapie

Volumn 14, Issue SUPPL. 1, 2010, Pages

  Vieillot, S ^a   Fenoglietto, P ^a   Ailleres N ^a   Hay, M H ^a   Dubois, J B ^a   Azria, D ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Atlas; Conformational radiotherapy; Prostate cancer; Radioanatomy; Target volumes

Indexed keywords

ARTICLE; BALLISTICS; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DOSIMETRY; HUMAN; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RISK ASSESSMENT; THREE DIMENSIONAL IMAGING;

BRACHYTHERAPY; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 78649762683     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(10)70020-2     Document Type: Article

References (32)

1. Aus G., Abbou C.C., Bolla M., Heidenreich A., Schmid H.P., Van Poppel H., et al. EAU Guidelines on Prostate Cancer. European Association of Urology 2005, 48:546-551.
2. Azria D., Aillères N., Llacer Moscardo C., Hay M.H., Dubois J.B., Fenoglietto P. Radiothérapie de conformation avec modulation d'intensité dans le cancer de la prostate: vers un nouveau standard ?. Cancer Radiother 2009, 13:409-415.
3. Beard C., Schultz D., Loffredo M., Cote K., Renshaw A.A., Hurwitz M.D., et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:403-407.
4. Boehmer D., Maingon P., Poortmans P., Baron M.H., Miralbell R., Remouchamps V., et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 2006, 79:259-269.
5. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106.
6. Bolla M., de Reijke T.M., Van Tienhoven G., Van den Bergh A.C., Oddens J., Poortmans P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
7. Chao K.K., Goldstein N.S., Yan D., Vargas C.E., Ghilezan M.I., Korman H.J., et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65:999-1007.
8. Chapet O., Quero L., Azria D., Bossi A., Hennequin C., Paparel P. L'irradiation pelvienne est-elle toujours justifiée dans le traitement des cancers de la prostate par irradiation exclusive ?. Cancer Radiother 2009, 13:416-422.
9. Chavaudra J., Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Cancer Radiother 2001, 5:472-478.
10. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., Kantoff P.W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004, 292:821-827.
11. D'Amico A.V., Renshaw A.A., Cote K., Hurwitz M., Beard C., Loffredo M., et al. Impact of the percentage of positive prostate cores on prostate cancerspecific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 2004, 22:3726-3732.
12. D'Amico A.V., Renshaw A.A., Sussman B., Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005, 294:440-447.
13. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Silver B., Henry L., et al. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol 2004, 4:171-175. discussion 177.
14. Dearnaley D.P., Sydes M.R., Graham J.D., Aird E.G., Bottomley D., Cowan R.A., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
15. Hanks G.E., Pajak T.F., Porter A., Grignon D., Brereton H., Venkatesan V., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
16. Kagawa K., Lee W.R., Schultheiss T.E., Hunt M.A., Shaer A.H., Hanks G.E. Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997, 38:319-325.
17. Kestin L., Goldstein N., Vicini F., Yan D., Korman H., Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. Int J Radiat Oncol Biol Phys 2002, 54:686-697.
18. Kuban D.A., Tucker S.L., Dong L., Starkschall G., Huang E.H., Cheung M.R., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
19. Lawton C.A., DeSilvio M., Roach M., Uhl V., Kirsch R., Seider M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69:646-655.
20. Palma D., Tyldesley S., Blood P., Liu M., Morris J., Pickles T. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys 2007, 67:1425-1429.
21. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. Jama 1997, 277:1445-1451.
22. Peeters S.T., Heemsbergen W.D., Koper P.C., van Putten W.L., Slot A., Dielwart M.F., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24:1990-1996.
23. Pilepich M.V., Winter K., John M.J., Mesic J.B., Sause W., Rubin P., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252.
24. Pilepich M.V., Winter K., Lawton C.A., Krisch R.E., Wolkov H.B., Movsas B., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
25. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
26. Roach M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
27. Roach M., Marquez C., Yuo H.S., Narayan P., Coleman L., Nseyo U.O., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994, 28:33-37.
28. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2003; 3:S29-33.
29. Guides procédures de radiothérapie externe 2007. Cancer Radiother 2008, 12:141-314. Société francaise de radiothérapie externe.
30. Steenbakkers R.J., Duppen J.C., Betgen A., Lotz H.T., Remeijer P., Fitton I., et al. Impact of knee support and shape of tabletop on rectum and prostate position. Int J Radiat Oncol Biol Phys 2004, 60:1364-1372.
31. Zelefsky M.J., Levin E.J., Hunt M., Yamada Y., Shippy A.M., Jackson A., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
32. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama 2005, 294:1233-1239.